Clinical trial researches combination drug therapy for myelodysplastic syndromes

Male doctor with female patient

Image credit: Canva

Myelodysplastic syndromes (MDS) are a group of diseases that affect the bone marrow, causing issues in the blood formation process and reducing blood cell counts. High-risk MDS can lead to leukemia. A clinical trial led by Steven Z. Pavletic, M.D., Ph.D., Senior Clinician in the Immune Deficiency Cellular Therapy Program, is researching a combination drug therapy for these disorders.

The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.

For more information, please contact Ashley E. Carpenter at (240) 760-6009 or identifier: NCT05918055

NCI Protocol ID: IRB001541

Official Title: A Phase I/II Trial of Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Posted on Wed, 11/22/2023